As­traZeneca, Boehringer In­gel­heim, GSK de­fend patent list­ings as Klobuchar amps up pres­sure

Sen. Amy Klobuchar (D-MN) is pres­sur­ing six phar­ma com­pa­nies to re­move im­prop­er­ly list­ed patents from the FDA’s Or­ange Book by the end of the month, af­ter the FTC in No­vem­ber sim­i­lar­ly chal­lenged a slew of patents for be­ing im­prop­er­ly list­ed.

In let­ters to Ab­b­Vie, As­traZeneca, Boehringer In­gel­heim, GSK, Vi­a­tris and Te­va sent Thurs­day, Klobuchar said that im­prop­er Or­ange Book list­ings hurt pa­tients be­cause they pre­vent cheap­er gener­ics from com­ing to mar­ket. She calls on the com­pa­nies to ei­ther re­move the patents from the Or­ange Book or pro­vide her with an ex­pla­na­tion for why they be­lieve the patents are prop­er­ly list­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER